What Is DSIP?
DSIP stands for Delta Sleep-Inducing Peptide.
It is a tiny peptide containing nine amino acids, making it a nonapeptide. FDA materials refer to the compound as emideltide.
DSIP was first isolated in the 1970s during experiments investigating substances that might naturally promote sleep.
Researchers initially became interested in it because experimental administration appeared to influence delta or slow-wave sleep.
That led to the name:
Delta Sleep-Inducing Peptide.
But the story became considerably more complicated as scientists continued studying it.
Is DSIP Really a Natural “Sleep Peptide”?
This is one of the biggest unresolved questions.
Early research suggested that DSIP-like material could be detected in the brain, blood and other tissues. Researchers subsequently investigated its possible relationships with:
- Sleep
- Circadian rhythms
- Stress
- Hormones
- Neurotransmitters
- Pain
- Drug withdrawal
However, scientists have struggled to identify a clear DSIP gene, precursor protein or specific DSIP receptor.
A major scientific review eventually described DSIP as a “still unresolved riddle,” concluding that its status as a natural sleep factor remained poorly documented.
So although the name makes DSIP sound like we’ve identified the body’s natural “sleep switch,” that’s much more certain than the science actually is.
Why Are Researchers Interested in It?
The obvious answer is sleep.
But DSIP research expanded far beyond simply making someone sleepy.
Older experimental research investigated potential effects involving:
sleep regulation → circadian rhythms → stress responses → neurotransmitters → hormonal signaling → pain → withdrawal.
A major early review described effects across several physiological systems, which led researchers to consider DSIP more of a potentially multifunctional regulatory peptide than a conventional sedative.
That’s an important distinction.
DSIP doesn’t appear to behave exactly like a traditional sleeping pill.
How Might DSIP Work?
This is where the answer becomes:
We don’t really know yet.
Unlike many compounds in our library, DSIP doesn’t have one clearly established receptor and signaling pathway that explains its effects.
Researchers have proposed interactions involving:
- Neurotransmitter systems
- Circadian regulation
- Neuroendocrine signaling
- Stress-response systems
- Endogenous opioid pathways
But no single mechanism has been definitively established.
That uncertainty is one of the reasons DSIP remains such an unusual peptide decades after its discovery.
What Does the Human Sleep Research Show?
There actually is human research.
But it’s old, small and inconsistent.
An early double-blind crossover experiment involved only six healthy volunteers. Researchers reported increased sleep during the observation period following DSIP and some improvements in subsequent nighttime sleep.
Another early study involving six people with chronic insomnia reported longer sleep duration, fewer interruptions and improved sleep quality.
Later studies weren’t nearly as convincing.
A 1987 controlled trial of people with insomnia found some changes in sleep measurements, but concluded that the overall improvement was of little clinical significance.
And a 1992 double-blind study involving 16 people with chronic insomnia found somewhat better sleep efficiency and shorter sleep latency, but the researchers concluded that the effects were weak and that short-term DSIP treatment was unlikely to provide major therapeutic benefit.
So the evidence isn’t:
“DSIP doesn’t affect sleep.”
Nor is it:
“DSIP is proven to treat insomnia.”
It’s closer to:
Small early studies produced interesting but inconsistent signals that were never confirmed through the kind of large modern trials we’d want today.
What About Deep Sleep?
Because it’s literally called Delta Sleep-Inducing Peptide, this is probably the claim people expect to be strongest.
Delta waves are strongly associated with slow-wave or deep sleep.
But the results aren’t nearly that simple.
For example, the 1987 insomnia study reported increases primarily in stage 2 sleep, while slow-wave sleep itself wasn’t significantly changed.
That means calling DSIP a proven “deep-sleep enhancer” is not justified.
Its name reflects the history of the compound—not a guarantee that administering it reliably increases deep sleep in humans.
What About Insomnia?
Insomnia is the condition with some of the most direct DSIP research.
Several small older clinical studies reported improvements in certain sleep measurements. One placebo-controlled study involving 14 people with severe chronic insomnia reported improved nighttime sleep and daytime performance during treatment.
But other controlled trials found much weaker effects.
Most importantly, these studies involved very small numbers of participants and were conducted decades ago.
There isn’t a large modern clinical-development program establishing DSIP as an effective insomnia treatment.
What About Circadian Rhythm?
Older DSIP research reported effects involving circadian and locomotor patterns, which helped generate interest in whether the peptide participates in broader sleep-wake regulation.
That’s why research areas such as:
body clock, sleep-wake cycle, circadian rhythm and disrupted sleep schedule
belong in our search system.
But DSIP hasn’t been established as a treatment for circadian-rhythm disorders.
What About Stress & Cortisol?
Experimental research has also explored DSIP’s relationship with the body’s stress-response systems.
Older studies reported effects involving hormonal levels and responses to experimentally induced stress, which contributed to theories that DSIP may act as a broader neuroendocrine regulatory peptide rather than simply a sleep-inducing substance.
This is where online claims about:
stress reduction, cortisol control and anxiety
often originate.
Those areas are scientifically interesting.
They are not established clinical benefits of DSIP.
What About Pain?
There is some surprisingly interesting old research here.
A 1984 pilot study involved only seven patients experiencing chronic pain conditions including migraines, headaches, tinnitus and psychogenic pain.
Six of seven reportedly experienced reduced pain during the study.
That’s interesting enough to justify further research.
It’s nowhere near enough evidence to establish DSIP as a treatment for chronic pain or migraines.
What About Withdrawal?
This is another unusual part of DSIP’s history.
An older clinical study administered DSIP to people experiencing alcohol or opioid withdrawal and reported improvements among many of the evaluable participants.
FDA specifically included opioid withdrawal among the proposed uses it evaluated during its July 2026 review of emideltide-related substances.
But this research is old and limited, and DSIP is not an established treatment for substance withdrawal.
What About Narcolepsy?
Narcolepsy was another use FDA considered during its 2026 evaluation.
However, research examining naturally occurring DSIP-like immunoreactivity in people with narcolepsy did not demonstrate a clear biomarker relationship.
There isn’t adequate clinical evidence establishing DSIP as a narcolepsy treatment.
Evidence Snapshot
Laboratory Research: Yes
Animal Research: Yes
Human Research: Yes, but mostly small and old
Human Insomnia Trials: Yes
Results for Sleep: Mixed
Modern Large Clinical Trials: Lacking
Established Mechanism/Receptor: No
FDA Approved: No
Overall Evidence: Interesting historical human research, but weak by modern clinical standards
DSIP is actually a great example of why saying “there are human studies” isn’t enough.
There are.
But study size, replication, consistency and research quality matter too.
What Do We Know?
We know DSIP is a defined nine-amino-acid peptide that has been investigated experimentally for decades.
We also know that administering synthetic DSIP produced measurable effects in some small human experiments involving sleep and sleep-wake behavior.
So DSIP isn’t purely an internet invention or something supported only by animal experiments.
There is legitimate scientific history behind it.
What Don’t We Know?
We don’t have strong modern evidence establishing that DSIP:
- Treats insomnia
- Reliably increases deep sleep
- Makes people fall asleep faster
- Improves sleep quality
- Treats narcolepsy
- Reduces anxiety
- Lowers cortisol
- Treats chronic stress
- Treats chronic pain
- Treats migraines
- Treats alcohol or opioid withdrawal
- Improves recovery
- Increases growth hormone
- Improves longevity
We also still don’t fully understand what DSIP’s natural biological role actually is.
That’s a pretty significant unanswered question for a compound discovered nearly 50 years ago.
What About Safety?
Small historical human studies generally did not identify major acute safety problems, but those studies were far too small to establish a comprehensive safety profile.
Absence of problems in a handful of participants isn’t equivalent to demonstrating long-term safety.
Modern information about repeated exposure, interactions, immunogenicity and less common adverse effects remains limited.
Research & Regulatory Status
DSIP/emideltide is not an FDA-approved medication.
FDA reviewed emideltide free base and emideltide acetate in July 2026 as substances nominated for possible use in 503A pharmacy compounding.
The proposed uses FDA evaluated were:
opioid withdrawal, chronic insomnia and narcolepsy.
FDA materials also state that neither emideltide nor its acetate form is a component of an FDA-approved drug.
Your Pep Resource Takeaway
DSIP has one of those names that makes the science sound much more settled than it is.
“Delta Sleep-Inducing Peptide” sounds like scientists discovered the peptide responsible for deep sleep.
They didn’t.
What they discovered was a fascinating nine-amino-acid peptide that produced some sleep-related effects in early experiments and then turned out to be far more biologically confusing than expected.
There are actual human trials—which gives DSIP more clinical history than many research peptides.
But they’re mostly tiny studies from the 1980s and early 1990s, and their results conflict.
So DSIP belongs in legitimate sleep research.
It just doesn’t belong in the category of proven sleep treatments.
Research Areas / Search Keywords
DSIP, Delta Sleep-Inducing Peptide, Delta Sleep Inducing Peptide, emideltide, sleep peptide, sleep research, better sleep research, poor sleep, trouble sleeping, can’t sleep, difficulty sleeping, sleep problems, insomnia, insomnia research, chronic insomnia, falling asleep, trouble falling asleep, sleep onset, sleep latency, staying asleep, waking during the night, nighttime waking, restless sleep, sleep quality, deep sleep, deep sleep research, delta sleep, delta waves, slow-wave sleep, slow wave sleep, NREM sleep, REM sleep, sleep stages, sleep cycle, sleep architecture, sleep-wake cycle, circadian rhythm, circadian rhythm research, body clock, disrupted sleep schedule, daytime tiredness, daytime sleepiness, fatigue research, low energy research, waking tired, brain health, neurological health, neuropeptide, nervous system research, neurotransmitters, neuroendocrine research, hypothalamus research, stress, chronic stress research, stress response, stress hormones, cortisol research, anxiety research, relaxation research, mood research, pain research, chronic pain research, migraine research, headache research, tinnitus research, opioid withdrawal research, opiate withdrawal research, alcohol withdrawal research, addiction research, substance withdrawal research, endogenous opioid system, narcolepsy research, sleep disorders, sleep regulation, natural sleep research, sleep peptides, recovery sleep research, hormone research, growth hormone research.
Educational Disclaimer: This profile is provided for educational and research-information purposes only. It is not medical advice and does not provide dosing, administration, treatment, or purchasing recommendations. DSIP/emideltide is not FDA approved, and its effectiveness and long-term safety have not been established.